Alnylam Reports Q3 2026 Financial Results
The company reported Q3 global net product revenues of $1,292M, driven by 52% growth in TTR revenues. It also announced expanded enrollment for a late-stage study and positive data for early-stage Huntington's disease assets.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed